枯草芽孢杆菌芽孢表面展示重组抗原疫苗研究进展*

枯草芽孢杆菌芽孢所具有的独特的理化特性及生理特征,使之成为新型的蛋白或酶类药物载体而倍受关注。简介了枯草芽孢杆菌芽孢结构特征,以及诱导机体产生的免疫反应,重点阐述了利用芽孢表面展示技术研制重组外源抗原疫苗,最后对芽孢表面展示外源抗原疫苗的应用前景进行了展望。     

枯草芽孢杆菌表面展示技术用于黏膜疫苗的研究进展

枯草杆菌全名枯草芽孢杆菌(Bacillus subtilis),因其优秀的益生特性及芽孢良好的抗逆性而备受研究者青睐,由于芽孢的特殊结构及独特的生理特性,是酶和免疫原等外源蛋白的理想锚定点。采用枯草杆菌进行芽孢表面展示被认为是表达高活性和高稳定性的外源蛋白的方法之一。本文主要对枯草杆菌芽孢表面展示抗原蛋白以生产黏膜疫苗的策略和应用前景进行综述。     

枯草芽孢杆菌表达系统及其启动子研究进展

枯草芽孢杆菌作为一种革兰氏阳性细菌,由于其具有非致病性、分泌蛋白能力强的特性和良好的发酵基础及生产技术,是目前原核表达系统中表达和分泌外源蛋白的理想宿主,成为原核表达系统中的一种重要的模式菌株。而实现外源蛋白的高效表达的关键因素之一是使用强并可控制的启动子。目前,枯草芽孢杆菌中常用的启动子为组成型、诱导物诱导型、时期特异性及自诱导型。详细介绍枯草芽孢杆菌表达系统以及其常用启动子的优缺点,并对克隆新的启动子的方法做了总结,旨为完善枯草表达系统和工业生产外源蛋白奠定基础。     

大肠杆菌-枯草芽孢杆菌穿梭质粒的构建及碱性蛋白酶的表达

构建了一个可以在大肠杆菌和枯草芽孢杆菌中复制,并可以在枯草芽孢杆菌中表达外源蛋白的穿梭表达载体pBE2R.该穿梭表达载体是以pBE2为基本骨架,引入来自pWB980质粒的P43强启动子,并在其下游引入嗜碱芽孢杆菌碱性蛋白酶信号肽和前肽构建而成.试验结果表明,该穿梭表达载体pBE2R可以在大肠杆DH5α和枯草芽孢杆菌WB600中稳定存在,并可以使外源蛋白在枯草芽孢杆菌进行分泌表达,同时也为碱性蛋白酶定向改造提供了高通量筛选平台.     

枯草芽胞杆菌孢子表面展示外源蛋白的研究

枯草芽胞杆菌孢子表面展示技术是最近十几年新兴的一种外源蛋白固定方法,已在酶学、疫苗学、靶向药物制备、金属污染治理等领域获得了广泛应用。以孢子衣壳蛋白为载体蛋白,已经成功地把许多抗原、酶和其他蛋白展示在孢子外表面。枯草芽胞杆菌孢子衣壳由多种衣壳蛋白组成,但可用做载体蛋白的并不多,且它们的特性不同。综合介绍了枯草芽胞杆菌孢子表面展示外源蛋白这种新型技术的具体机理,及其在国内外各领域应用的研究进展。     

基因串联策略强化枯草芽孢杆菌终止子的功能及其在基因表达中的应用

在底盘微生物中使用高性能终止子能够显著增强基因终止效率,维持新合成mRNA的稳定性,提升外源基因表达性能.而目前缺乏专一用于枯草芽孢杆菌的终止子元件,限制了复杂功能基因电路的设计.[目的]在枯草芽孢杆菌中挖掘新的高性能终止子,并进一步重新设计,丰富适用于这一底盘的高性能人工终止子.[方法]将枯草芽孢杆菌终止子和枯草芽孢...     

以CotC为分子载体在枯草芽孢杆菌表面展示海藻糖合酶

海藻糖是自然界中普遍存在的一种非还原性双糖,是一种极好的天然干燥剂和保鲜剂。海藻糖合酶能够催化α,α-1,4-糖苷键连接的麦芽糖直接转化为α,α-1,1-糖苷键连接的海藻糖,是生产海藻糖的首选。为获得具有良好展示效果的海藻糖合酶,将其高效稳定的展示于枯草芽孢杆菌芽孢表面,实验同时分别选取增强型绿色荧光蛋白(EGFP)和海藻糖合酶(Tres)作为模型蛋白,以来自枯草芽孢杆菌的芽孢衣壳蛋白Cot C作为枯草芽杆菌表面展示的锚定蛋白进行表面展示研究。利用流式细胞仪分析EGFP在芽孢表面展示的情况,结果表明芽孢衣壳蛋白Cot C可以将EGFP固定在芽孢的表面。然后将荧光蛋白基因egfp通过酶切替换为海藻糖合酶基因tres,将重组菌株使用p H7.5的缓冲液清洗并重悬,与底物浓度为30%的麦芽糖在50℃水浴条件下作用2h,反应产物利用HPLC检测,能够检测到海藻糖峰,通过计算得到的酶活为252U/ml。说明海藻糖合酶基因通过与芽孢衣壳蛋白Cot C融合后可被展示在芽孢的表面。     

无性繁殖芽孢杆菌和链霉菌用的运载体

运载体是由一个编码某一核糖体特异结合位点的DNA序列,来自枯草芽孢杆菌(Bacillus subtilis)Veg。促进子和一个编码所需蛋白的基因组构起来的,许多芽孢杆菌和链霉菌就利用了这样一些运载体生产出了外源蛋白质。这些运载体的优点,形体小,全能性表达。利用枯草芽孢杆菌和链霉菌代替大肠     

枯草芽孢杆菌感受态研究新进展

在枯草芽孢杆菌中,感受态的形成受到一种二元信号转导系统的调节,这种系统对胞外的感受态信息素浓度作出感应而激活晚期感受态基因的表达。各种晚期感受态蛋白分别负责外源DNA的吸附、吸收和内源化,它们共同构成了DNA的运输系统。初步探讨了枯草芽孢杆菌感受态调节在细胞生长和进化中的意义。     

以CotX为分子载体在枯草芽胞杆菌芽胞表面展示绿色荧光蛋白

芽胞衣壳蛋白CotB、CotC、CotG等可作为芽胞表面展示外源蛋白的分子载体,制备口服重组疫苗或具有催化活性的重组酶。CotX为枯草芽胞杆菌Bacillussubtilis芽胞衣壳中的另一种结构蛋白。为证明CotX能否作为分子载体将外源蛋白展示在芽胞表面,本研究将cotX基因与绿色荧光蛋白基因gfp的编码序列进行基因重组,构建融合表达CotX-GFP的整合型重组质粒,将该质粒转化枯草芽胞杆菌,筛选重组菌株并诱导产生芽胞,观察到重组芽胞表面具有GFP绿色荧光。结果表明枯草芽胞杆菌的芽胞衣壳蛋白CotX位于芽胞衣壳外层,可作为芽胞表面展示外源蛋白的载体分子。     

细菌芽胞—— 一种新型的疫苗载体

杆菌属的芽胞作为益生菌已经应用于人和动物的食品生产和细菌疗法.目前,芽胞作为一种新型的疫苗载体,开始用于破伤风、炭疽等疫苗的研究.与目前的第二代疫苗相比,细菌芽胞热稳定性好,遗传操作方便,是一种理想的疫苗载体.本文就其作为疫苗载体的相关研究进行综述.     

全球结核病疫苗研究进展

本文旨在对全球结核病疫苗研究进展进行系统综述,描述国际上目前进入临床试验不同阶段的新型疫苗,包括重组卡介苗、亚单位疫苗、治疗性疫苗等,分析我国结核病疫苗研究现状,介绍国际研究发展趋势,如人类疫苗计划、全细胞疫苗、多阶段疫苗等,并对存在的问题和挑战进行讨论,展望未来发展趋势。     

Anthrax vaccine design: strategies to achieve comprehensive protection against spore,bacillus, and toxin

The successful use of Bacillus anthracis as a lethal biological weapon has prompted renewed research interest in the development of more effective vaccines against anthrax. The disease consists of three critical components: spore, bacillus, and toxin, elimination of any of which confers at least partial protection against anthrax. Current remedies rely on postexposure antibiotics to eliminate bacilli and pre- and postexposure vaccination to target primarily toxins. Vaccines effective against toxin have been licensed for human use, but need improvement. Vaccines against bacilli have recently been developed by us and others. Whether effective vaccines will be developed against spores is still an open question. An ideal vaccine would confer simultaneous protection against spores, bacilli, and toxins. One step towards this goal is our dually active vaccine, designed to destroy both bacilli and toxin. Existing and potential strategies towards potent and effective anthrax vaccines are discussed in this review.     

Recombinant Mycobacterium bovis BCG producing the circumsporozoite protein of Plasmodium falciparum FCC-1/HN strain induces strong immune responses in BALB/c mice

The current vaccine against tuberculosis, Mycobacterium bovis strain bacillus Calmette-Guerin (BCG), offers potential advantages as a live, innately immunogenic vaccine vehicle for expression and delivery of protective recombinant antigens. Malaria is one of the severest parasitic diseases in humans especially in the developing world. No efficacious vaccine is currently available. However, circumsporozoite protein (CSP) is a malaria vaccine candidate currently undergoing clinical trials. We analyzed the immune response to recombinant BCG (rBCG) vaccine expressing Plasmodium falciparum CSP (BCG-CSP) under the control of heat shock protein 70 promoter in BALB/c mice. The lymphocytes proliferative response to P. falciparum soluble antigen was significantly higher than those in the groups of BCG and normal saline, and the production of cytokines (IFN-gamma and IL-2) in response to malaria antigen was significantly higher in rBCG and BCG groups than control group of normal saline. A specific IgG antibody response against P. falciparum antigen of CSP was also characterized. The booster injection could enhance the production of cytokine, proliferation responses of spleen lymphocytes and the antibodies titer of BCG-CSP. The results in the study demonstrated that rBCG vaccine producing CSP is an appropriate vaccine for further evaluation in non-human primates.     

Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method

Conventional parenteral injection of vaccines is limited in its ability to induce locally-produced immune responses in the respiratory tract, and has logistical disadvantages in widespread vaccine administration. Recent studies suggest that intranasal delivery or vaccination in the respiratory tract with recombinant viral vectors can enhance immunogenicity and protection against respiratory diseases such as influenza and tuberculosis, and can offer more broad-based generalized protection by eliciting durable mucosal immune responses. Controlled aerosolization is a method to minimize vaccine particle size and ensure delivery to the lower respiratory tract. Here, we characterize the dynamics of aerosolization and show the effects of vaccine concentration on particle size, vector viability, and the actual delivered dose of an aerosolized adenoviral vector. In addition, we demonstrate that aerosol delivery of a recombinant adenoviral vaccine encoding H1N1 hemagglutinin is immunogenic and protects ferrets against homologous viral challenge. Overall, aerosol delivery offers comparable protection to intramuscular injection, and represents an attractive vaccine delivery method for broad-based immunization campaigns.     

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance

An efficacious vaccine strategy must be capable of inducing strong responses of an appropriate phenotype that are long lasting and sufficiently broad to prevent pathogen escape mechanisms. In the present study, we use anti-CD25 mAb to augment vaccine-induced immunity in mice. We demonstrate that coformulation of Ab and poxviral- or adenoviral-vectored vaccines induces significantly increased T cell responses to a malaria Ag; prior anti-CD25 Ab administration was not required for this effect. Furthermore, this vaccination approach subverts immunodominant epitope hierarchies by enhancing responses to subdominant epitopes induced by recombinant modified vaccinia virus Ankara immunization. Administration of anti-CD25 with a vaccine also induces more durable immunity compared with vaccine alone; significantly higher T cell responses were observed 100 days after the primary immunization. Enhanced immunogenicity is observed for multiple vaccine types with enhanced CD4+ and CD8+ T cell responses induced by bacillus Calmette-Guérin and a recombinant subunit protein vaccine to hepatitis B virus and with multiple Ags of tumor, viral, bacterial, and parasitic origin. Vaccine strategies incorporating anti-CD25 lead to improved protection against pre-erythrocytic malaria challenge. These data underpin new strategies for the design and development of more efficacious vaccines in clinical settings.     

Secretory delivery of recombinant proteins in attenuated Salmonella strains: potential and limitations of Type I protein transporters

Live attenuated Salmonella strains have been extensively explored as oral delivery systems for recombinant vaccine antigens and effector proteins with immunoadjuvant and immunomodulatory potential. The feasibility of this approach was demonstrated in human vaccination trials for various antigens. However, immunization efficiencies with live vaccines are generally significantly lower compared to those monitored in parenteral immunizations with the same vaccine antigen. This is, at least partly, due to the lack of secretory expression systems, enabling large-scale extracellular delivery of vaccine and effector proteins by these strains. Because of their low complexity and the terminal location of the secretion signal in the secreted protein, Type I (ATP-binding cassette) secretion systems appear to be particularly suited for development of such recombinant extracellular expression systems. So far, the Escherichia coli hemolysin system is the only Type I secretion system, which has been adapted to recombinant protein secretion in Salmonella. However, this system has a number of disadvantages, including low secretion capacity, complex genetic regulation, and structural restriction to the secreted protein, which eventually hinder high-level in vivo delivery of recombinant vaccines and effector proteins. Thus, the development of more efficient recombinant protein secretion systems, based on Type I exporters can help to improve efficacies of live recombinant Salmonella vaccines. Type I secretion systems, mediating secretion of bacterial surface layer proteins, such as RsaA in Caulobacter crescentus, are discussed as promising candidates for improved secretory delivery systems.     

Molecular cloning and sequencing of the merozoite surface antigen 2 gene from Plasmodium falciparum strain FCC-1/HN and expression of the gene in mycobacteria

Strain bacillus Calmette-Guerin (BCG) of Mycobacterium bovis has been used as a live bacterial vaccine to immunize more than 3 billion people against tuberculosis. In an attempt to use this vaccine strain as a vehicle for protective antigens, the gene encoding merozoite surface antigen 2 (MSA2) was amplified from strain FCC-1/HN Plasmodium falciparum genome, sequenced, and expressed in M. bovis BCG under the control of an expression cassette carrying the promoter of heat shock protein 70 (HSP70) from Mycobacterium tuberculosis. The recombinant shuttle plasmid pBCG/MSA2 was introduced into mycobacteria by electroporation, and the recombinant mycobacteria harboring pBCG/MSA2 could be induced by heating to express MSA2; the molecular mass of recombinant MSA2 was about 31 kDa. This first report of expression of the full-length P. falciparum MSA2 gene in BCG provides evidence for use of the HSP70 promoter in expressing a foreign gene in BCG and in development of BCG as a multivalent vectoral vaccine for malaria.     

Effects of alpha- and beta-D-glucose on germination of spores of Bacillus megaterium QM B1551.

The effects of D-glucose anomers on the germination of dormant spores of Bacillus megaterium QM B1551 were studied, alpha-D-Glucose (1 mM) slightly initiated the germination of the dormant spores during 10 min incubation at 37 degrees C, while about 60% of the dormant spores became germinated with beta-D-glucose (1 mM) in the same conditions. From the above observations and the finding that only a trace amount of alpha- or beta-D-glucose may bind with the dormant spores, it is speculated that the beta-D-glucose-stereospecific receptor site for the germination exists on the surface of the dormant spores of the bacillus.     

对研发新型结核病疫苗的分析和展望

结核病是公共卫生当前面临的重要问题。由于BCG预防效果不佳,研究和开发新型结核病疫苗显得必须且急迫。新型结核病疫苗的研究开发路径和观念也经历了变迁,当前主流的研发路径有重组BCG或重组结核菌、重组痘病毒或重组腺病毒载体疫苗、蛋白质亚单位或重组融合蛋白质亚单位疫苗三类,它们在疫苗效力前景,抗原选型、配方、剂型,免疫应答,疫苗生产,疫苗质量控制,临床前研究动物试验,临床试验和使用,对结核病公共卫生政策的影响等方面各有优劣。新型结核病疫苗的成功研发,还需要病原学、发病机制、免疫学和疫苗研发科学的进一步努力。